Albumin
Biological
CSL Behring
Total Payments
$111,065
Transactions
44
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $900.00 | 1 | 1 |
| 2019 | $104,045 | 39 | 0 |
| 2018 | $6,120 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $111,065 | 44 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin rIX-FP in Patients With Hemophilia B | CSL Behring | $104,045 | 0 |
| A Randomized Trial to Prevent Congenital Cytomegalovirus CMV | CSL Behring | $6,120 | 0 |
| Laboratory Testing for COVID Project | CSL Behring | $900.00 | 1 |
Top Doctors Receiving Payments for Albumin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $110,165 | 43 |
| , M.D | Hematology | Rochester, MN | $900.00 | 1 |
Ad
Manufacturing Companies
- CSL Behring $111,065
Product Information
- Type Biological
- Total Payments $111,065
- Total Doctors 1
- Transactions 44
About Albumin
Albumin is a biological associated with $111,065 in payments to 1 healthcare providers, recorded across 44 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2018 to 2020. In 2020, $900.00 was paid across 1 transactions to 1 doctors.
The most common payment nature for Albumin is "Unspecified" ($111,065, 100.0% of total).
Albumin is associated with 3 research studies, including "A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin rIX-FP in Patients With Hemophilia B" ($104,045).